Institution
Medical University of Graz
Education•Graz, Steiermark, Austria•
About: Medical University of Graz is a education organization based out in Graz, Steiermark, Austria. It is known for research contribution in the topics: Population & Medicine. The organization has 5684 authors who have published 12349 publications receiving 417282 citations.
Topics: Population, Medicine, Cancer, Transplantation, Vitamin D and neurology
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Chelating agents are effective therapies for most patients with Wilson disease; D-penicillamine and trientine produce comparable outcomes, although D- penicillamines had a higher rate of adverse events.
162 citations
••
UCL Institute of Neurology1, Epilepsy Society2, University of Porto3, University Medical Center Utrecht4, University of Bonn5, University of Melbourne6, King's College London7, Beaumont Hospital8, Royal College of Surgeons in Ireland9, University of Zurich10, Western General Hospital11, University of Eastern Finland12, University of Tampere13, Université libre de Bruxelles14, Medical University of Graz15, Medical University of Vienna16, University of Liège17, University of Edinburgh18, Royal Melbourne Hospital19, University of Genoa20, Thomas Jefferson University21, Rowan University22, Children's Hospital of Philadelphia23, Instituto Nacional de Saúde Dr. Ricardo Jorge24, Ruhr University Bochum25, University of Marburg26, University of Tübingen27, University of Erlangen-Nuremberg28, Royal Children's Hospital29, Florey Institute of Neuroscience and Mental Health30
TL;DR: Genetic analysis and meta-analysis suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febs.
Abstract: Epilepsy comprises several syndromes, amongst the most common being mesial temporal lobe epilepsy with hippocampal sclerosis. Seizures in mesial temporal lobe epilepsy with hippocampal sclerosis are typically drug-resistant, and mesial temporal lobe epilepsy with hippocampal sclerosis is frequently associated with important co-morbidities, mandating the search for better understanding and treatment. The cause of mesial temporal lobe epilepsy with hippocampal sclerosis is unknown, but there is an association with childhood febrile seizures. Several rarer epilepsies featuring febrile seizures are caused by mutations in SCN1A, which encodes a brain-expressed sodium channel subunit targeted by many anti-epileptic drugs. We undertook a genome-wide association study in 1018 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 7552 control subjects, with validation in an independent sample set comprising 959 people with mesial temporal lobe epilepsy with hippocampal sclerosis and 3591 control subjects. To dissect out variants related to a history of febrile seizures, we tested cases with mesial temporal lobe epilepsy with hippocampal sclerosis with (overall n = 757) and without (overall n = 803) a history of febrile seizures. Meta-analysis revealed a genome-wide significant association for mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures at the sodium channel gene cluster on chromosome 2q24.3 [rs7587026, within an intron of the SCN1A gene, P = 3.36 × 10(-9), odds ratio (A) = 1.42, 95% confidence interval: 1.26-1.59]. In a cohort of 172 individuals with febrile seizures, who did not develop epilepsy during prospective follow-up to age 13 years, and 6456 controls, no association was found for rs7587026 and febrile seizures. These findings suggest SCN1A involvement in a common epilepsy syndrome, give new direction to biological understanding of mesial temporal lobe epilepsy with hippocampal sclerosis with febrile seizures, and open avenues for investigation of prognostic factors and possible prevention of epilepsy in some children with febrile seizures.
161 citations
••
TL;DR: Established bone turnover markers do not reflect fracture risk in idiopathic male and premenopausal osteoporosis and the role of microRNAs (miRNAs) in these patients is currently unclear, but specific serum miRNA profiles are strongly related to bone pathologies.
Abstract: Context: Established bone turnover markers do not reflect fracture risk in idiopathic male and premenopausal osteoporosis and the role of microRNAs (miRNAs) in these patients is currently unclear. miRNAs are a class of small non-coding RNAs that regulate gene expression and bone tissue homeostasis. They are considered a new class of endocrine regulators with promising potential as biomarkers. Objective: Evaluation of circulating miRNA signatures in male and female subjects with idiopathic and postmenopausal osteoporotic low-traumatic fractures. Design, Setting, and Patients: This was a case-control study of cross-sectional design of 36 patients with prevalent low-traumatic fractures and 39 control subjects Main Outcome Measures: One hundred eighty-seven miRNAs were quantified in serum by qPCR, compared between groups and correlated with established bone turnover markers. Results: Significant differences in serum levels of circulating miRNAs were identified in all three subgroups (46 in premenopausal, 52 i...
160 citations
••
TL;DR: Although palifermin reduced severe functional OM, its role in the management of locally advanced HNC during chemoradiotherapy remains to be elucidated.
Abstract: Purpose Oral mucositis (OM) is a debilitating toxicity of chemoradiotherapy for head and neck cancer (HNC). This randomized, placebo-controlled, double-blind study evaluated the efficacy and safety of palifermin to reduce OM associated with definitive chemoradiotherapy for locally advanced HNC. Patients and Methods Patients receiving conventionally fractionated radiotherapy (2.0 Gy/d, 5 days/wk to 70 Gy) with cisplatin (100 mg/m2 on days 1, 22, and 43) received palifermin (180 μg/kg) or placebo before starting chemoradiotherapy and then once weekly for 7 weeks. The primary end point was the incidence of severe, observable, and functional OM (WHO grade 3 to 4). Results The palifermin (n = 94) and placebo (n = 94) arms were well balanced. The incidence of severe OM was significantly lower for palifermin than for placebo (54% v 69%; P = .041). In the palifermin arm, median time to severe OM was delayed (47 v 35 days), median duration of severe OM was shortened (5 v 26 days), and the incidence of xerostomia g...
160 citations
••
TL;DR: A new total-generalized-variation (TGV) based method for QSM reconstruction, which incorporates individual steps of phase unwrapping, background field removal and dipole inversion in a single iteration, thus yielding a robust solution to the reconstruction problem is proposed.
160 citations
Authors
Showing all 5763 results
Name | H-index | Papers | Citations |
---|---|---|---|
Ian J. Deary | 166 | 1795 | 114161 |
James F. Wilson | 146 | 677 | 101883 |
Nancy L. Pedersen | 145 | 890 | 94696 |
William Wijns | 127 | 752 | 95517 |
Andrew Simmons | 102 | 460 | 36608 |
Franz Fazekas | 101 | 629 | 49775 |
Hans-Peter Hartung | 100 | 810 | 49792 |
Michael Trauner | 98 | 667 | 35543 |
Dietmar Fuchs | 97 | 1119 | 39758 |
Funda Meric-Bernstam | 96 | 753 | 36803 |
Ulf Landmesser | 94 | 564 | 46096 |
Aysegul A. Sahin | 93 | 322 | 30038 |
Frank Madeo | 92 | 269 | 45942 |
Takayoshi Ohkubo | 91 | 631 | 69634 |
Jürgen C. Becker | 90 | 637 | 28741 |